Figure 2. IRF8 protects against Ang II-induced cardiomyocyte hypertrophy in vitro.
(a) Representative images of cardiomyocytes infected with AdshIRF8 or AdIRF8 and treated with Ang II (1 μM) for 48 h (red: nuclear; green: α-actinin; scale bar, 50 μm). (b) Quantitative results of the cell surface area of cardiomyocytes infected with AdshIRF8 or AdIRF8 in response to Ang II (1 μM) for 48 h (n≥50 cells per experimental group). (c) Real-time PCR assays were performed to determine the mRNA levels of ANP and β-MHC in IRF8 knockdown and overexpressed cells after treatment with PBS and Ang II for 48 h. (n=4 samples per experimental group, *P<0.05 versus AdshRNA or AdGFP /PBS, #P<0.05 versus AdshRNA or AdGFP /Ang II). The data represent as the mean±s.d. Statistical analysis was carried out by two-way analysis of variance with general linear model procedures using a univariate approach.